Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study.
Bestgen B, Jones S, Thathy V, Kuemmerle A, Barcelo C, Haouala A, Gossen D, Marx MW, Di Resta I, Szramowska M, Webster RA, Llewellyn S, Ritacco DA, Yeo T, Leroy D, Barber BE, Fidock DA, Griffin P, Lickliter J, Chalon S.
Bestgen B, et al. Among authors: jones s.
Lancet Infect Dis. 2024 Dec 18:S1473-3099(24)00664-9. doi: 10.1016/S1473-3099(24)00664-9. Online ahead of print.
Lancet Infect Dis. 2024.
PMID: 39708824
Free article.